StockData

Kura Oncology vs Verastem

KURA and VSTM side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How KURA and VSTM compare

Kura Oncology and Verastem are about the same size, with market caps of $666M and $671M.

Verastem keeps more of each dollar of sales as profit, with a net margin of −232% compared with −369% at Kura Oncology.

Verastem scores higher on the StockData Score (3 against 1 for Kura Oncology), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricKURAVSTM
Size and price
Market cap$666M$671M
Share price$7.49$7.41
Change, 1 year−33.2%−1.9%
Change, 5 years−46.5%−77.0%
Beta (5Y)2.302.66
Employees260102
StockData Score
Total score13 (better)
Valuation score00
Growth score01 (better)
Performance score01 (better)
Health score11
Dividend score00
Valuation
P/S8.4×7.7× (better)
P/B37.1×13.4× (better)
FCF yield−13.4%–
Growth
Revenue growth, 5Y average–−19.0%
Profitability
Operating margin−394%−183% (better)
Net margin−369%−232% (better)
FCF margin−112%–
Return on equity−225% (better)−471%
Financial health
Debt / equity0.55–
Interest coverage−227.1×−108.3× (better)
Current ratio3.60 (better)2.25
Altman Z-score−3.56 (better)−7.37
Piotroski F-score14 (better)
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions98.0%109%
Held by insiders2.7%1.8%
Insider net buying, 12 months$512K (better)−$816K
Short interest, % of float14.6%22.1%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.